Veterinary and Comparative Oncology

Papers
(The TQCC of Veterinary and Comparative Oncology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Outcomes of 35 dogs with craniomaxillofacial osteosarcoma treated with stereotactic body radiation therapy25
Issue Information24
Ultrasound‐guided core needle biopsy in dogs with thyroid carcinoma21
Serum thymidine kinase 1 activity as a prognostic biomarker in dogs with chemotherapy‐treated diffuse large B‐cell lymphoma21
Effects of a high‐protein, increased‐fibre, dry diet supplemented with omega‐3 fatty acids on quality of life in dogs undergoing chemotherapy17
Investigation of efficacy of two different chemotherapy protocols used in neoadjuvant chemotherapy in clinical stages II–IV canine malignant mammary tumours17
Issue Information15
Treatment of feline intermediate to high‐grade alimentary lymphoma: A retrospective evaluation of 55 cats treated with the VAPC combination chemotherapy protocol (2017–2021)15
Timely adjuvant chemotherapy improves outcome in dogs with non‐metastatic splenic hemangiosarcoma undergoing splenectomy14
High lysyl oxidase expression is an indicator of poor prognosis in dogs with cutaneous mast cell tumours14
Plasma cell‐free DNA in canine lymphoma patients as a novel material for genotyping14
Dysregulated miRNAs in a canine model of haemangiosarcoma metastatic to the brain13
Dose and Duration of Upfront Steroid Administration Have no Prognostic Impact in Dogs With Multicentric Diffuse Large B‐Cell Lymphoma12
Standardisation of canine meningioma grading: Inter‐observer agreement and recommendations for reproducible histopathologic criteria12
Pre‐operative neoadjuvant vinblastine‐prednisolone in canine mast cell tumours: A single‐centre retrospective cohort study12
Combining radiation therapy with zoledronate for the treatment of osteo‐invasive feline oral squamous cell carcinoma11
Risk factors associated with the onset of lomustine‐induced neutropenia in tumour‐bearing dogs11
Outcome of dogs treated with chemotherapy for mesothelioma: A retrospective clinical study on 40 cases and a literature review11
Descriptive analysis of haemangiosarcoma occurrence in dogs enrolled in the Golden Retriever lifetime study11
Blood biomarkers for canine cancer, from human to veterinary oncology11
Issue Information10
Polarisation Sensitive Optical Coherence Tomography Image Characteristics for Gastrointestinal Tumours and Normal Tissues at Surgical Margins in Dogs10
Issue Information10
9
Author Index9
Prognostic Value of a Histopathological Scoring System and the Ki67 Proliferation Index in Dogs With Phaeochromocytoma9
Expression of Concern: Tumour necrosis factor‐alpha‐induced protein 8 (TNFAIP8) expression associated with cell survival and death in cancer cell lines infected with canine distemper virus9
Cover Image9
Efficacy and toxicity of carboplatin in the treatment of macroscopic mesenchymal neoplasia in dogs9
Chronic adrenergic stress and generation of myeloid‐derived suppressor cells: Implications for cancer immunotherapy in dogs9
Issue Information9
Corrigendum9
8
Use of Cystourethroscopy to Define the Gross Tumour Volume in Radiation Treatment Planning for Canine Genitourinary Carcinomas8
Effects of Lipophilic Statins on Cell Viability and Tissue Factor Expression in Canine Haemangiosarcoma Cells8
Issue Information8
Immunophenotyping and Mutation Analysis of Canine Intestinal T‐Cell Lymphoma: A Comparative Pathological Study of Human Enteropathy‐Associated T‐Cell Lymphoma8
7
Fractionated oral dosing and its effect on cyclophosphamide pharmacokinetics in dogs with high‐grade multicentric lymphoma7
Frontal sinus carcinoma in forty‐one dogs (2001–2022)7
7
Epidemiology of canine cutaneous round cell tumours on the canary archipelago in Spain7
Spotlight on capecitabine for the treatment of unresectable or metastatic carcinoma of various origin: A retrospective study of 25 dogs7
Issue Information7
Classification and Prognostication of B‐Cell and T‐Cell Multicentric Lymphoma in Dogs Using Serum MicroRNAs7
Issue Information6
Serum Lactate Dehydrogenase as a Potential Prognostic Biomarker in Dogs With Appendicular Osteosarcoma6
6
Issue Information6
6
Blood Neutrophil‐to‐Lymphocyte Ratio as a Potential Prognostic Marker in Dogs ≤10 kg With Multicentric Lymphoma6
Author Index6
DNA Methylation and Its Effects on TRIM29 Gene Expression in the Equine Sarcoid Tissue6
Use of Lomustine and Prednisolone as First‐Line Treatment in Canine Multicentric Lymphoma6
Evaluation of serum interleukin 2 receptor and beta‐2‐microglobulin as prognostic factors for canine lymphoma: A pilot study5
5
Vinorelbine as a Rescue Treatment for Canine Histiocytic Sarcoma: A Multicentre Retrospective Study of 18 Dogs5
Quantification of circulating tumour cells over time in dogs with appendicular osteosarcoma5
Defining the relevance of surgical margins. Part two: Strategies to improve prediction of recurrence risk5
Phase 1 Dose Escalation of Single‐Agent Mechlorethamine in Dogs With Lymphoma5
Configuration of pathologic fractures in dogs with osteosarcoma following stereotactic body radiation therapy: A retrospective analysis5
Sodium iodide symporter immunolabelling as a predictor of clinical iodide uptake in canine thyroid carcinoma: A preliminary study5
Clinical Response to Imatinib Mesylate and Toxicity Profile in 35 Dogs With Mast Cell Tumours5
Retrospective analysis of outcome and prognostic factors of subcutaneous mast cell tumours in dogs undergoing surgery with or without adjuvant treatment5
Favourable Prognostic Significance of HER2 Mutations in Canine Pulmonary Adenocarcinoma Following Surgical Resection5
Comparison of the anticancer effects of various statins on canine oral melanoma cells5
Molecular Classification Based on the Gene Expression Profiles in Canine Histiocytic Sarcoma Cells5
Isolation of Tumour‐Derived Extracellular Vesicles From the Plasma of Dogs Affected by Intracranial Tumours Showing Heterologous and Cross‐Species Tropism: A Pilot Study5
Evaluating VEGFR2 as a Target for Anti‐Tumour Therapy in Canine Melanoma5
Overactivation of Signal Transducer and Activator of Transcription 3 in Canine Hepatocellular Carcinoma and Its Prognostic Significance5
Evaluation of the health‐related quality of life in dogs following intracranial meningioma resection using a specifically developed questionnaire5
5
Description and efficacy of a response‐based “QUAD” cyclical hypofractionated palliative‐intent radiation protocol in dogs with macroscopic solid tumours: 108 cases4
Evaluation of the anti‐tumour activity of Coriolus versicolor polysaccharopeptide (I'm‐Yunity) alone or in combination with doxorubicin for canine splenic hemangiosarcoma4
Correlation between computed tomography and histological evaluation of nodal metastasis in dogs with mast cell tumours4
Evaluating the relevance of surgical margins. Part one: The problems with current methodology4
The role of toceranib phosphate in dogs with non‐mast cell neoplasia: A systematic review4
Sentinel lymph node mapping in canine mast cell tumours using a preoperative radiographic indirect lymphography: Technique description and results in 138 cases4
Identification of potential plasma protein biomarkers for feline pancreatic carcinoma by liquid chromatography tandem mass spectrometry4
Half‐Body Radiation Therapy Results in a Prolonged Progression‐Free Interval in Canine High‐Grade Lymphoma After First Remission4
VCS abstract4
Impact of 10% Dose Reductions and Duration of Treatment Delays in the Management of Chemotherapy‐Induced Neutropenia in Dogs Treated With Common Chemotherapy Protocols: A Single‐Centre Experience4
Stereotactic body radiation therapy as an alternative to adrenalectomy for the treatment of pheochromocytomas in 8 dogs4
Developing a translational murine‐to‐canine pathway for anIL‐2/agonistanti‐CD40antibody cancer immunotherapy4
Cyclical 10‐day dosing of melphalan for canine multiple myeloma4
Mass spectrometric‐based assessment of the serum kappa to lambda immunoglobulin light chain ratio (κ:λ) in dogs with immunoglobulin secretory diseases4
0.11141490936279